Cromos Pharma supporting Blood Cancer Awareness Month
September is Blood Cancer Awareness Month. Approximately 1.24 million blood cancer cases occur annually worldwide, accounting for almost 6% of all cancer cases. In the US, blood cancers are the third leading cause of cancer deaths yet the impact of these cancers is under recognized. Despite recent progress in blood cancer research, more than 1/3 of blood cancer patients still do not survive five years after diagnosis[i]. This September, Cromos Pharma is pleased to raise awareness of blood cancers and reaffirm its commitment to supporting clinical research to make treatment breakthroughs.
Types of blood cancers
Most blood cancers, also called hematologic cancers, start in the bone marrow, which is where blood is produced. Common types include Leukaemia, Lymphoma, Myeloma, Myelodysplastic syndromes (MDS), Myeloproliferative neoplasms (MPN), and Aplastic anaemia[ii].
Signs and symptoms
As with all cancers, early diagnosis and early treatment can dramatically increase survival rates. Although early signs of blood cancers vary from person to person there are some common warning flags including:
- Unexpected weight loss
- Unexplained bruising and bleeding
- Lumps or swellings
- Shortness of breath
- Drenching night sweats
- Extreme fatigue
- Frequent infections
- Recurrent fevers
Contact your doctor if you have any concerns about cancer including blood cancers.
Cromos Pharma’s expertise in hematology-oncology
Cromos Pharma has extensive experience in managing all aspects of clinical trials in hematology-oncology in all Phases, I, II, III and post market/observational. Oncology studies represent nearly 20% of all our work and we have successfully managed 20+ studies in hematology-oncology. Regulatory inspections and site audits attest to the highest quality of clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
Patient recruitment specialists accelerating clinical research
Cromos Pharma, a US-based international clinical research organization (CRO), combines global expertise with in-depth experience and knowledge in Central and Eastern Europe. We have an extensive PI/site network and unparalleled access to patient databases and key opinion leaders. These relationships have helped us achieve an unrivalled record for patient recruitment – our team has met or reduced enrollment timelines in 95% of trials conducted over our sixteen year history. Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program.
Contact bd@cromospharma.com to arrange an introductory meeting and find out how our experience can benefit your next clinical project.
References:
[i] https://www.lls.org/article/september-blood-cancer-awareness-month
[ii] https://www.leukaemia.org.au/blood-cancer-information/types-of-blood-cancer/
